Neurothera Labs（C0A）株式概要ニューロセラ・ラボ社は臨床段階の製薬会社を運営している。 詳細C0A ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績0/6財務の健全性5/6配当金0/6リスク分析過去1年間で収益は34.5%減少しました 収益が 100 万ドル未満 ( $856K )German市場と比較して、過去 3 か月間の株価の変動が非常に大きい過去1年間で株主の希薄化は大幅に進んだ +2 さらなるリスクすべてのリスクチェックを見るC0A Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW480,107 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINRODA480,107 investors already sharing narrativesYour Fair Value€Current Price€0.0881.4k% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-4m1m2016201920222025202620282031Revenue US$856.0kEarnings US$124.7kAdvancedSet Fair ValueView all narrativesNeurothera Labs Inc. 競合他社TFF PharmaceuticalsSymbol: MUN:0K30Market cap: €9.7mBiofronteraSymbol: XTRA:B8FKMarket cap: €15.3mCantourage GroupSymbol: XTRA:HIGHMarket cap: €68.8mMPH Health CareSymbol: DB:93M1Market cap: €102.3m価格と性能株価の高値、安値、推移の概要Neurothera Labs過去の株価現在の株価CA$0.08852週高値CA$0.1552週安値CA$0.08ベータ-0.221ヶ月の変化7.35%3ヶ月変化6.31%1年変化n/a3年間の変化n/a5年間の変化n/aIPOからの変化-4.89%最新ニュースお知らせ • Jul 15Neurothera Labs Announces Initiation of Phase IIb Clinical Trial at Hannover Medical School in Germany for Innovative Treatment of Tourette SyndromeNeuroThera Labs announced the initiation of its Phase IIb clinical trial site at Hannover Medical School, Hanover, Germany, for SCI-110, its proprietary cannabinoid-based treatment candidate for Tourette Syndrome in adults. The trial, which previously received regulatory clearance from Germany’s Federal Institute for Drugs and Medical Devices and MHH's ethics committee, is now advancing towards the next stage at Hannover Medical School, one of the key clinical sites of the study. SCI-110 combines dronabinol with the endocannabinoid-like palmitoylethanolamide in an innovative one dosage form designed to reduce tics and comorbid symptoms in adults with TS while minimizing side effects. In addition to Hannover Medical School, the trial will be conducted at Yale Child Study Center in New Haven, Connecticut, and Tel Aviv Sourasky Medical Center in Tel Aviv, Israel. Building on the positive safety and efficacy results from the Phase IIa study, which showed an average tic reduction of 21% across the entire participants sample, as measured by the gold standard, Yale Global Tic Severity Scale Total Tic Score scale, the Phase IIb study is a randomized, double-blind, placebo-controlled, cross-over trial designed to evaluate the efficacy, safety, and tolerability of daily oral SCI-110. Patients aged 18-65 will be randomized to receive either SCI-110 or placebo, with the primary efficacy endpoint being the change in tic severity measured by the Yale Global Tic Severity Scale at weeks 12 and 26 compared to the baseline. Safety will be assessed through monitoring of adverse events.お知らせ • Jul 01Neurothera Labs Inc. announced that it expects to receive CAD 5.00175 million in fundingNeuroThera Labs Inc. announced a non-brokered private placement of up to 37,050,000 units at an issue price of CAD 0.135 for gross proceeds of CAD 5,001,750 on June 30, 2026. Each Unit will be comprised of one common share in the capital of the Company and one transferable common share purchase warrant entitling the holder thereof to acquire one common share in the capital of the Company at a price of CAD 0.18 per Unit Warrant Share for a period of 24 months from the date of issuance thereof. Certain insiders of the Company may acquire Offered Units in the Offering. The Unit Shares and Unit Warrants issued under the Offering will be subject to a statutory hold period expiring four months and one day from the date of issuance of such Offered Units. The Company may pay finder's fees on a portion of the Offering, subject to applicable securities legislation. Closing of the Offering is subject to approval of the TSX Venture Exchange. It is not anticipated that any new insiders will be created, nor that any change of control will occur, as a result of the Offering. Any participation by insiders of the Company in the Offering will be on the same terms as arm’s length investors.お知らせ • Jun 04Neurothera Labs Inc. (TSXV:NTLX) completed the acquisition of 54.01% stake in CliniQuantum Ltd.Neurothera Labs Inc. (TSXV:NTLX) entered into a definitive share purchase agreement to acquire 54.01% stake in CliniQuantum Ltd. for $9 million on March 9, 2026. In consideration for the Purchased Shares, the Company will issue an aggregate of 56,600,000 common shares in the capital of the Company (the "Consideration Shares") to the Selling Shareholders, representing an aggregate value of approximately $9.5 million based on the 20-day volume weighted average trading price of the Neurothera's common shares on the TSX Venture Exchange. In addition to the Consideration Shares, the Selling Shareholders may be entitled to receive earn-out payments of up to $2.5 million in the aggregate (the "Earn-Out Payments"), payable in cash and/or common shares of Neurothera at the sole discretion of Neurothera, contingent upon the achievement of the certain milestones, including $0.5 million for each of the first three patent applications filed by CliniQ with the United States Patent and Trademark Office or the European Patent Office, up to a maximum of $1.5 million in the aggregate; and an amount equal to 7.0% of any fundraising proceeds raised by Neurothera, up to a maximum of $1 million in the aggregate. The Earn-Out Payments, if any, are payable during the three-year period following the closing of the Transaction. The Approval of the Neurothera Labs's Board of Directors and Shareholders has been received Closing of the Transaction is expected to occur within 30 days following the submission of the application for the Israeli tax ruling to the Israeli Tax Authority, subject to TSXV approval and satisfaction or waiver of all closing conditions. As of May 27, 2026, the outside date for the completion of the transaction has been extended to June 1, 2026. On May 28, 2026, parties received a conditional regulatory approval from the TSX Venture Exchange. I.F.S. Consulting and Investments (2009) Ltd acted as fairness opinion provider for Neurothera Labs Inc. Neurothera Labs Inc. (TSXV:NTLX) completed the acquisition of 54.01% stake in CliniQuantum Ltd. on June 3, 2026. Amitay Weiss, a director of SciSparc Ltd. and SciSparc Nutraceuticals Inc., is also a director of Quantum X Labs Ltd., which holds the remaining approximately 45.98% of the ordinary shares of CliniQuantum. Closing of the Transaction has occurred following receipt of all necessary corporate approvals and final acceptance of the TSXV.お知らせ • Mar 17Neurothera Labs Inc. Clearmind Medicine Inc. Collaboration Leads to Patent Application for Depression TherapySciSparc Ltd. reported that pursuant to NeuroThera’s ongoing collaboration with Clearmind Medicine Inc., a patent application has been filed by Clearmind with the Intellectual Property Department in Hong Kong, China, for a innovative combination therapy designed to treat major depressive disorder (MDD). This innovative treatment combines Clearmind’s proprietary 5-methoxy-2-aminoindane (MEAI) with Palmitoylethanolamide (PEA) sourced by NeuroThera. The patent filing underscores the promise of this MEAI-PEA synergy as a non-hallucinogenic neuroplastogen option for combating depression, a condition affecting more than 332 million people globally, according to the World Health Organization article titled “Depressive Disorder (Depression)”, published in August 2025.お知らせ • Mar 11CliniQuantum Ltd. entered into a definitive share purchase agreement to acquire Neurothera Labs Inc. (TSXV:NTLX) from SciSparc Ltd. (NasdaqCM:SPRC) in a reverse merger transaction.CliniQuantum Ltd. entered into a definitive share purchase agreement to acquire Neurothera Labs Inc. (TSXV:NTLX) from SciSparc Ltd. (NasdaqCM:SPRC) in a reverse merger transaction on March 9, 2026. In consideration for the Purchased Shares, the Company will issue an aggregate of 56,600,000 common shares in the capital of the Company (the "Consideration Shares") to the Selling Shareholders, representing an aggregate value of approximately $9.5 million based on the 20-day volume weighted average trading price of the Neurothera's common shares on the TSX Venture Exchange. In addition to the Consideration Shares, the Selling Shareholders may be entitled to receive earn-out payments of up to $2.5 million in the aggregate (the "Earn-Out Payments"), payable in cash and/or common shares of Neurothera at the sole discretion of Neurothera, contingent upon the achievement of the certain milestones, including $0.5 million for each of the first three patent applications filed by CliniQ with the United States Patent and Trademark Office or the European Patent Office, up to a maximum of $1.5 million in the aggregate; and an amount equal to 7.0% of any fundraising proceeds raised by Neurothera, up to a maximum of $1 million in the aggregate. The Earn-Out Payments, if any, are payable during the three-year period following the closing of the Transaction. Closing of the Transaction is expected to occur within 30 days following the submission of the application for the Israeli tax ruling to the Israeli Tax Authority, subject to TSXV approval and satisfaction or waiver of all closing conditions.最新情報をもっと見るRecent updatesお知らせ • Jul 15Neurothera Labs Announces Initiation of Phase IIb Clinical Trial at Hannover Medical School in Germany for Innovative Treatment of Tourette SyndromeNeuroThera Labs announced the initiation of its Phase IIb clinical trial site at Hannover Medical School, Hanover, Germany, for SCI-110, its proprietary cannabinoid-based treatment candidate for Tourette Syndrome in adults. The trial, which previously received regulatory clearance from Germany’s Federal Institute for Drugs and Medical Devices and MHH's ethics committee, is now advancing towards the next stage at Hannover Medical School, one of the key clinical sites of the study. SCI-110 combines dronabinol with the endocannabinoid-like palmitoylethanolamide in an innovative one dosage form designed to reduce tics and comorbid symptoms in adults with TS while minimizing side effects. In addition to Hannover Medical School, the trial will be conducted at Yale Child Study Center in New Haven, Connecticut, and Tel Aviv Sourasky Medical Center in Tel Aviv, Israel. Building on the positive safety and efficacy results from the Phase IIa study, which showed an average tic reduction of 21% across the entire participants sample, as measured by the gold standard, Yale Global Tic Severity Scale Total Tic Score scale, the Phase IIb study is a randomized, double-blind, placebo-controlled, cross-over trial designed to evaluate the efficacy, safety, and tolerability of daily oral SCI-110. Patients aged 18-65 will be randomized to receive either SCI-110 or placebo, with the primary efficacy endpoint being the change in tic severity measured by the Yale Global Tic Severity Scale at weeks 12 and 26 compared to the baseline. Safety will be assessed through monitoring of adverse events.お知らせ • Jul 01Neurothera Labs Inc. announced that it expects to receive CAD 5.00175 million in fundingNeuroThera Labs Inc. announced a non-brokered private placement of up to 37,050,000 units at an issue price of CAD 0.135 for gross proceeds of CAD 5,001,750 on June 30, 2026. Each Unit will be comprised of one common share in the capital of the Company and one transferable common share purchase warrant entitling the holder thereof to acquire one common share in the capital of the Company at a price of CAD 0.18 per Unit Warrant Share for a period of 24 months from the date of issuance thereof. Certain insiders of the Company may acquire Offered Units in the Offering. The Unit Shares and Unit Warrants issued under the Offering will be subject to a statutory hold period expiring four months and one day from the date of issuance of such Offered Units. The Company may pay finder's fees on a portion of the Offering, subject to applicable securities legislation. Closing of the Offering is subject to approval of the TSX Venture Exchange. It is not anticipated that any new insiders will be created, nor that any change of control will occur, as a result of the Offering. Any participation by insiders of the Company in the Offering will be on the same terms as arm’s length investors.お知らせ • Jun 04Neurothera Labs Inc. (TSXV:NTLX) completed the acquisition of 54.01% stake in CliniQuantum Ltd.Neurothera Labs Inc. (TSXV:NTLX) entered into a definitive share purchase agreement to acquire 54.01% stake in CliniQuantum Ltd. for $9 million on March 9, 2026. In consideration for the Purchased Shares, the Company will issue an aggregate of 56,600,000 common shares in the capital of the Company (the "Consideration Shares") to the Selling Shareholders, representing an aggregate value of approximately $9.5 million based on the 20-day volume weighted average trading price of the Neurothera's common shares on the TSX Venture Exchange. In addition to the Consideration Shares, the Selling Shareholders may be entitled to receive earn-out payments of up to $2.5 million in the aggregate (the "Earn-Out Payments"), payable in cash and/or common shares of Neurothera at the sole discretion of Neurothera, contingent upon the achievement of the certain milestones, including $0.5 million for each of the first three patent applications filed by CliniQ with the United States Patent and Trademark Office or the European Patent Office, up to a maximum of $1.5 million in the aggregate; and an amount equal to 7.0% of any fundraising proceeds raised by Neurothera, up to a maximum of $1 million in the aggregate. The Earn-Out Payments, if any, are payable during the three-year period following the closing of the Transaction. The Approval of the Neurothera Labs's Board of Directors and Shareholders has been received Closing of the Transaction is expected to occur within 30 days following the submission of the application for the Israeli tax ruling to the Israeli Tax Authority, subject to TSXV approval and satisfaction or waiver of all closing conditions. As of May 27, 2026, the outside date for the completion of the transaction has been extended to June 1, 2026. On May 28, 2026, parties received a conditional regulatory approval from the TSX Venture Exchange. I.F.S. Consulting and Investments (2009) Ltd acted as fairness opinion provider for Neurothera Labs Inc. Neurothera Labs Inc. (TSXV:NTLX) completed the acquisition of 54.01% stake in CliniQuantum Ltd. on June 3, 2026. Amitay Weiss, a director of SciSparc Ltd. and SciSparc Nutraceuticals Inc., is also a director of Quantum X Labs Ltd., which holds the remaining approximately 45.98% of the ordinary shares of CliniQuantum. Closing of the Transaction has occurred following receipt of all necessary corporate approvals and final acceptance of the TSXV.お知らせ • Mar 17Neurothera Labs Inc. Clearmind Medicine Inc. Collaboration Leads to Patent Application for Depression TherapySciSparc Ltd. reported that pursuant to NeuroThera’s ongoing collaboration with Clearmind Medicine Inc., a patent application has been filed by Clearmind with the Intellectual Property Department in Hong Kong, China, for a innovative combination therapy designed to treat major depressive disorder (MDD). This innovative treatment combines Clearmind’s proprietary 5-methoxy-2-aminoindane (MEAI) with Palmitoylethanolamide (PEA) sourced by NeuroThera. The patent filing underscores the promise of this MEAI-PEA synergy as a non-hallucinogenic neuroplastogen option for combating depression, a condition affecting more than 332 million people globally, according to the World Health Organization article titled “Depressive Disorder (Depression)”, published in August 2025.お知らせ • Mar 11CliniQuantum Ltd. entered into a definitive share purchase agreement to acquire Neurothera Labs Inc. (TSXV:NTLX) from SciSparc Ltd. (NasdaqCM:SPRC) in a reverse merger transaction.CliniQuantum Ltd. entered into a definitive share purchase agreement to acquire Neurothera Labs Inc. (TSXV:NTLX) from SciSparc Ltd. (NasdaqCM:SPRC) in a reverse merger transaction on March 9, 2026. In consideration for the Purchased Shares, the Company will issue an aggregate of 56,600,000 common shares in the capital of the Company (the "Consideration Shares") to the Selling Shareholders, representing an aggregate value of approximately $9.5 million based on the 20-day volume weighted average trading price of the Neurothera's common shares on the TSX Venture Exchange. In addition to the Consideration Shares, the Selling Shareholders may be entitled to receive earn-out payments of up to $2.5 million in the aggregate (the "Earn-Out Payments"), payable in cash and/or common shares of Neurothera at the sole discretion of Neurothera, contingent upon the achievement of the certain milestones, including $0.5 million for each of the first three patent applications filed by CliniQ with the United States Patent and Trademark Office or the European Patent Office, up to a maximum of $1.5 million in the aggregate; and an amount equal to 7.0% of any fundraising proceeds raised by Neurothera, up to a maximum of $1 million in the aggregate. The Earn-Out Payments, if any, are payable during the three-year period following the closing of the Transaction. Closing of the Transaction is expected to occur within 30 days following the submission of the application for the Israeli tax ruling to the Israeli Tax Authority, subject to TSXV approval and satisfaction or waiver of all closing conditions.株主還元C0ADE PharmaceuticalsDE 市場7D0.2%-2.0%0.1%1Yn/a36.5%-0.5%株主還元を見る業界別リターン: C0AがGerman Pharmaceuticals業界に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。リターン対市場: C0A German市場に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。価格変動Is C0A's price volatile compared to industry and market?C0A volatilityC0A Average Weekly Movement22.2%Pharmaceuticals Industry Average Movement6.2%Market Average Movement5.3%10% most volatile stocks in DE Market12.7%10% least volatile stocks in DE Market2.7%安定した株価: C0Aの株価は、 German市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 過去 1 年間のC0Aのボラティリティの変化を判断するには データが不十分です。会社概要設立従業員CEO（最高経営責任者ウェブサイトn/an/aOz Adlerwww.neurothera.comニューロセラ・ラボ社は臨床段階の製薬会社を運営している。同社はTHCおよび/または非精神活性CBDをベースとした医薬品開発プログラムに従事している：SCI-110はトゥレット症候群の治療薬、SCI-210はアルツハイマー病と興奮症の治療薬、SCI-210はASDとてんかん重積状態の治療薬である。ニューロセラ・ラボ社の前身はミザIIIベンチャーズ社。同社はカナダのバンクーバーを拠点としている。2023年2月23日現在、Neurothera Labs Inc.はSciSparc Ltd.の子会社として運営されている。もっと見るNeurothera Labs Inc. 基礎のまとめNeurothera Labs の収益と売上を時価総額と比較するとどうか。C0A 基礎統計学時価総額€9.01m収益（TTM）-€3.62m売上高(TTM)€752.34k12.0xP/Sレシオ-2.5xPER（株価収益率C0A は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計C0A 損益計算書（TTM）収益US$856.00k売上原価US$225.00k売上総利益US$631.00kその他の費用US$4.75m収益-US$4.12m直近の収益報告Dec 31, 2025次回決算日該当なし一株当たり利益（EPS）-0.049グロス・マージン73.72%純利益率-481.66%有利子負債／自己資本比率144.1%C0A の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/23 01:22終値2026/07/23 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Neurothera Labs Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Jul 15Neurothera Labs Announces Initiation of Phase IIb Clinical Trial at Hannover Medical School in Germany for Innovative Treatment of Tourette SyndromeNeuroThera Labs announced the initiation of its Phase IIb clinical trial site at Hannover Medical School, Hanover, Germany, for SCI-110, its proprietary cannabinoid-based treatment candidate for Tourette Syndrome in adults. The trial, which previously received regulatory clearance from Germany’s Federal Institute for Drugs and Medical Devices and MHH's ethics committee, is now advancing towards the next stage at Hannover Medical School, one of the key clinical sites of the study. SCI-110 combines dronabinol with the endocannabinoid-like palmitoylethanolamide in an innovative one dosage form designed to reduce tics and comorbid symptoms in adults with TS while minimizing side effects. In addition to Hannover Medical School, the trial will be conducted at Yale Child Study Center in New Haven, Connecticut, and Tel Aviv Sourasky Medical Center in Tel Aviv, Israel. Building on the positive safety and efficacy results from the Phase IIa study, which showed an average tic reduction of 21% across the entire participants sample, as measured by the gold standard, Yale Global Tic Severity Scale Total Tic Score scale, the Phase IIb study is a randomized, double-blind, placebo-controlled, cross-over trial designed to evaluate the efficacy, safety, and tolerability of daily oral SCI-110. Patients aged 18-65 will be randomized to receive either SCI-110 or placebo, with the primary efficacy endpoint being the change in tic severity measured by the Yale Global Tic Severity Scale at weeks 12 and 26 compared to the baseline. Safety will be assessed through monitoring of adverse events.
お知らせ • Jul 01Neurothera Labs Inc. announced that it expects to receive CAD 5.00175 million in fundingNeuroThera Labs Inc. announced a non-brokered private placement of up to 37,050,000 units at an issue price of CAD 0.135 for gross proceeds of CAD 5,001,750 on June 30, 2026. Each Unit will be comprised of one common share in the capital of the Company and one transferable common share purchase warrant entitling the holder thereof to acquire one common share in the capital of the Company at a price of CAD 0.18 per Unit Warrant Share for a period of 24 months from the date of issuance thereof. Certain insiders of the Company may acquire Offered Units in the Offering. The Unit Shares and Unit Warrants issued under the Offering will be subject to a statutory hold period expiring four months and one day from the date of issuance of such Offered Units. The Company may pay finder's fees on a portion of the Offering, subject to applicable securities legislation. Closing of the Offering is subject to approval of the TSX Venture Exchange. It is not anticipated that any new insiders will be created, nor that any change of control will occur, as a result of the Offering. Any participation by insiders of the Company in the Offering will be on the same terms as arm’s length investors.
お知らせ • Jun 04Neurothera Labs Inc. (TSXV:NTLX) completed the acquisition of 54.01% stake in CliniQuantum Ltd.Neurothera Labs Inc. (TSXV:NTLX) entered into a definitive share purchase agreement to acquire 54.01% stake in CliniQuantum Ltd. for $9 million on March 9, 2026. In consideration for the Purchased Shares, the Company will issue an aggregate of 56,600,000 common shares in the capital of the Company (the "Consideration Shares") to the Selling Shareholders, representing an aggregate value of approximately $9.5 million based on the 20-day volume weighted average trading price of the Neurothera's common shares on the TSX Venture Exchange. In addition to the Consideration Shares, the Selling Shareholders may be entitled to receive earn-out payments of up to $2.5 million in the aggregate (the "Earn-Out Payments"), payable in cash and/or common shares of Neurothera at the sole discretion of Neurothera, contingent upon the achievement of the certain milestones, including $0.5 million for each of the first three patent applications filed by CliniQ with the United States Patent and Trademark Office or the European Patent Office, up to a maximum of $1.5 million in the aggregate; and an amount equal to 7.0% of any fundraising proceeds raised by Neurothera, up to a maximum of $1 million in the aggregate. The Earn-Out Payments, if any, are payable during the three-year period following the closing of the Transaction. The Approval of the Neurothera Labs's Board of Directors and Shareholders has been received Closing of the Transaction is expected to occur within 30 days following the submission of the application for the Israeli tax ruling to the Israeli Tax Authority, subject to TSXV approval and satisfaction or waiver of all closing conditions. As of May 27, 2026, the outside date for the completion of the transaction has been extended to June 1, 2026. On May 28, 2026, parties received a conditional regulatory approval from the TSX Venture Exchange. I.F.S. Consulting and Investments (2009) Ltd acted as fairness opinion provider for Neurothera Labs Inc. Neurothera Labs Inc. (TSXV:NTLX) completed the acquisition of 54.01% stake in CliniQuantum Ltd. on June 3, 2026. Amitay Weiss, a director of SciSparc Ltd. and SciSparc Nutraceuticals Inc., is also a director of Quantum X Labs Ltd., which holds the remaining approximately 45.98% of the ordinary shares of CliniQuantum. Closing of the Transaction has occurred following receipt of all necessary corporate approvals and final acceptance of the TSXV.
お知らせ • Mar 17Neurothera Labs Inc. Clearmind Medicine Inc. Collaboration Leads to Patent Application for Depression TherapySciSparc Ltd. reported that pursuant to NeuroThera’s ongoing collaboration with Clearmind Medicine Inc., a patent application has been filed by Clearmind with the Intellectual Property Department in Hong Kong, China, for a innovative combination therapy designed to treat major depressive disorder (MDD). This innovative treatment combines Clearmind’s proprietary 5-methoxy-2-aminoindane (MEAI) with Palmitoylethanolamide (PEA) sourced by NeuroThera. The patent filing underscores the promise of this MEAI-PEA synergy as a non-hallucinogenic neuroplastogen option for combating depression, a condition affecting more than 332 million people globally, according to the World Health Organization article titled “Depressive Disorder (Depression)”, published in August 2025.
お知らせ • Mar 11CliniQuantum Ltd. entered into a definitive share purchase agreement to acquire Neurothera Labs Inc. (TSXV:NTLX) from SciSparc Ltd. (NasdaqCM:SPRC) in a reverse merger transaction.CliniQuantum Ltd. entered into a definitive share purchase agreement to acquire Neurothera Labs Inc. (TSXV:NTLX) from SciSparc Ltd. (NasdaqCM:SPRC) in a reverse merger transaction on March 9, 2026. In consideration for the Purchased Shares, the Company will issue an aggregate of 56,600,000 common shares in the capital of the Company (the "Consideration Shares") to the Selling Shareholders, representing an aggregate value of approximately $9.5 million based on the 20-day volume weighted average trading price of the Neurothera's common shares on the TSX Venture Exchange. In addition to the Consideration Shares, the Selling Shareholders may be entitled to receive earn-out payments of up to $2.5 million in the aggregate (the "Earn-Out Payments"), payable in cash and/or common shares of Neurothera at the sole discretion of Neurothera, contingent upon the achievement of the certain milestones, including $0.5 million for each of the first three patent applications filed by CliniQ with the United States Patent and Trademark Office or the European Patent Office, up to a maximum of $1.5 million in the aggregate; and an amount equal to 7.0% of any fundraising proceeds raised by Neurothera, up to a maximum of $1 million in the aggregate. The Earn-Out Payments, if any, are payable during the three-year period following the closing of the Transaction. Closing of the Transaction is expected to occur within 30 days following the submission of the application for the Israeli tax ruling to the Israeli Tax Authority, subject to TSXV approval and satisfaction or waiver of all closing conditions.
お知らせ • Jul 15Neurothera Labs Announces Initiation of Phase IIb Clinical Trial at Hannover Medical School in Germany for Innovative Treatment of Tourette SyndromeNeuroThera Labs announced the initiation of its Phase IIb clinical trial site at Hannover Medical School, Hanover, Germany, for SCI-110, its proprietary cannabinoid-based treatment candidate for Tourette Syndrome in adults. The trial, which previously received regulatory clearance from Germany’s Federal Institute for Drugs and Medical Devices and MHH's ethics committee, is now advancing towards the next stage at Hannover Medical School, one of the key clinical sites of the study. SCI-110 combines dronabinol with the endocannabinoid-like palmitoylethanolamide in an innovative one dosage form designed to reduce tics and comorbid symptoms in adults with TS while minimizing side effects. In addition to Hannover Medical School, the trial will be conducted at Yale Child Study Center in New Haven, Connecticut, and Tel Aviv Sourasky Medical Center in Tel Aviv, Israel. Building on the positive safety and efficacy results from the Phase IIa study, which showed an average tic reduction of 21% across the entire participants sample, as measured by the gold standard, Yale Global Tic Severity Scale Total Tic Score scale, the Phase IIb study is a randomized, double-blind, placebo-controlled, cross-over trial designed to evaluate the efficacy, safety, and tolerability of daily oral SCI-110. Patients aged 18-65 will be randomized to receive either SCI-110 or placebo, with the primary efficacy endpoint being the change in tic severity measured by the Yale Global Tic Severity Scale at weeks 12 and 26 compared to the baseline. Safety will be assessed through monitoring of adverse events.
お知らせ • Jul 01Neurothera Labs Inc. announced that it expects to receive CAD 5.00175 million in fundingNeuroThera Labs Inc. announced a non-brokered private placement of up to 37,050,000 units at an issue price of CAD 0.135 for gross proceeds of CAD 5,001,750 on June 30, 2026. Each Unit will be comprised of one common share in the capital of the Company and one transferable common share purchase warrant entitling the holder thereof to acquire one common share in the capital of the Company at a price of CAD 0.18 per Unit Warrant Share for a period of 24 months from the date of issuance thereof. Certain insiders of the Company may acquire Offered Units in the Offering. The Unit Shares and Unit Warrants issued under the Offering will be subject to a statutory hold period expiring four months and one day from the date of issuance of such Offered Units. The Company may pay finder's fees on a portion of the Offering, subject to applicable securities legislation. Closing of the Offering is subject to approval of the TSX Venture Exchange. It is not anticipated that any new insiders will be created, nor that any change of control will occur, as a result of the Offering. Any participation by insiders of the Company in the Offering will be on the same terms as arm’s length investors.
お知らせ • Jun 04Neurothera Labs Inc. (TSXV:NTLX) completed the acquisition of 54.01% stake in CliniQuantum Ltd.Neurothera Labs Inc. (TSXV:NTLX) entered into a definitive share purchase agreement to acquire 54.01% stake in CliniQuantum Ltd. for $9 million on March 9, 2026. In consideration for the Purchased Shares, the Company will issue an aggregate of 56,600,000 common shares in the capital of the Company (the "Consideration Shares") to the Selling Shareholders, representing an aggregate value of approximately $9.5 million based on the 20-day volume weighted average trading price of the Neurothera's common shares on the TSX Venture Exchange. In addition to the Consideration Shares, the Selling Shareholders may be entitled to receive earn-out payments of up to $2.5 million in the aggregate (the "Earn-Out Payments"), payable in cash and/or common shares of Neurothera at the sole discretion of Neurothera, contingent upon the achievement of the certain milestones, including $0.5 million for each of the first three patent applications filed by CliniQ with the United States Patent and Trademark Office or the European Patent Office, up to a maximum of $1.5 million in the aggregate; and an amount equal to 7.0% of any fundraising proceeds raised by Neurothera, up to a maximum of $1 million in the aggregate. The Earn-Out Payments, if any, are payable during the three-year period following the closing of the Transaction. The Approval of the Neurothera Labs's Board of Directors and Shareholders has been received Closing of the Transaction is expected to occur within 30 days following the submission of the application for the Israeli tax ruling to the Israeli Tax Authority, subject to TSXV approval and satisfaction or waiver of all closing conditions. As of May 27, 2026, the outside date for the completion of the transaction has been extended to June 1, 2026. On May 28, 2026, parties received a conditional regulatory approval from the TSX Venture Exchange. I.F.S. Consulting and Investments (2009) Ltd acted as fairness opinion provider for Neurothera Labs Inc. Neurothera Labs Inc. (TSXV:NTLX) completed the acquisition of 54.01% stake in CliniQuantum Ltd. on June 3, 2026. Amitay Weiss, a director of SciSparc Ltd. and SciSparc Nutraceuticals Inc., is also a director of Quantum X Labs Ltd., which holds the remaining approximately 45.98% of the ordinary shares of CliniQuantum. Closing of the Transaction has occurred following receipt of all necessary corporate approvals and final acceptance of the TSXV.
お知らせ • Mar 17Neurothera Labs Inc. Clearmind Medicine Inc. Collaboration Leads to Patent Application for Depression TherapySciSparc Ltd. reported that pursuant to NeuroThera’s ongoing collaboration with Clearmind Medicine Inc., a patent application has been filed by Clearmind with the Intellectual Property Department in Hong Kong, China, for a innovative combination therapy designed to treat major depressive disorder (MDD). This innovative treatment combines Clearmind’s proprietary 5-methoxy-2-aminoindane (MEAI) with Palmitoylethanolamide (PEA) sourced by NeuroThera. The patent filing underscores the promise of this MEAI-PEA synergy as a non-hallucinogenic neuroplastogen option for combating depression, a condition affecting more than 332 million people globally, according to the World Health Organization article titled “Depressive Disorder (Depression)”, published in August 2025.
お知らせ • Mar 11CliniQuantum Ltd. entered into a definitive share purchase agreement to acquire Neurothera Labs Inc. (TSXV:NTLX) from SciSparc Ltd. (NasdaqCM:SPRC) in a reverse merger transaction.CliniQuantum Ltd. entered into a definitive share purchase agreement to acquire Neurothera Labs Inc. (TSXV:NTLX) from SciSparc Ltd. (NasdaqCM:SPRC) in a reverse merger transaction on March 9, 2026. In consideration for the Purchased Shares, the Company will issue an aggregate of 56,600,000 common shares in the capital of the Company (the "Consideration Shares") to the Selling Shareholders, representing an aggregate value of approximately $9.5 million based on the 20-day volume weighted average trading price of the Neurothera's common shares on the TSX Venture Exchange. In addition to the Consideration Shares, the Selling Shareholders may be entitled to receive earn-out payments of up to $2.5 million in the aggregate (the "Earn-Out Payments"), payable in cash and/or common shares of Neurothera at the sole discretion of Neurothera, contingent upon the achievement of the certain milestones, including $0.5 million for each of the first three patent applications filed by CliniQ with the United States Patent and Trademark Office or the European Patent Office, up to a maximum of $1.5 million in the aggregate; and an amount equal to 7.0% of any fundraising proceeds raised by Neurothera, up to a maximum of $1 million in the aggregate. The Earn-Out Payments, if any, are payable during the three-year period following the closing of the Transaction. Closing of the Transaction is expected to occur within 30 days following the submission of the application for the Israeli tax ruling to the Israeli Tax Authority, subject to TSXV approval and satisfaction or waiver of all closing conditions.
